Pfizer Inc Asset Resilience Ratio
Pfizer Inc asset resilience ratio. Pfizer Inc (PFIZ34) has an Asset Resilience Ratio of 5.33% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pfizer Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pfizer Inc (2014–2025)
Asset resilience ratio of Pfizer Inc from 2014 to 2025. This chart shows how Pfizer Inc's Asset Resilience Ratio has changed over time. Read PFIZ34 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Pfizer Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 0% |
| Short-term Investments | R$10.72 Billion | 5.33% |
| Total Liquid Assets | R$10.72 Billion | 5.33% |
Asset Resilience Insights
- Limited Liquidity: Pfizer Inc maintains only 5.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pfizer Inc Industry Peers by Asset Resilience Ratio
Compare Pfizer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Sanofi
MX:SNYN |
Drug Manufacturers - General | 0.64% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Pfizer Inc Asset Resilience Ratio by Year (2014–2025)
Pfizer Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Pfizer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.53% | R$13.60 Billion ≈ $2.67 Billion |
R$208.16 Billion ≈ $40.84 Billion |
-3.06pp |
| 2024-12-31 | 9.60% | R$20.48 Billion ≈ $4.02 Billion |
R$213.40 Billion ≈ $41.87 Billion |
+3.99pp |
| 2023-12-31 | 5.60% | R$12.69 Billion ≈ $2.49 Billion |
R$226.50 Billion ≈ $44.44 Billion |
-5.92pp |
| 2022-12-31 | 11.53% | R$22.73 Billion ≈ $4.46 Billion |
R$197.21 Billion ≈ $38.70 Billion |
-5.59pp |
| 2021-12-31 | 17.12% | R$31.07 Billion ≈ $6.10 Billion |
R$181.48 Billion ≈ $35.61 Billion |
+9.20pp |
| 2020-12-31 | 7.92% | R$12.22 Billion ≈ $2.40 Billion |
R$154.23 Billion ≈ $30.26 Billion |
+2.84pp |
| 2019-12-31 | 5.09% | R$8.53 Billion ≈ $1.67 Billion |
R$167.59 Billion ≈ $32.88 Billion |
-6.01pp |
| 2018-12-31 | 11.10% | R$17.69 Billion ≈ $3.47 Billion |
R$159.42 Billion ≈ $31.28 Billion |
+0.24pp |
| 2017-12-31 | 10.86% | R$18.65 Billion ≈ $3.66 Billion |
R$171.80 Billion ≈ $33.71 Billion |
+1.97pp |
| 2016-12-31 | 8.89% | R$15.26 Billion ≈ $2.99 Billion |
R$171.62 Billion ≈ $33.67 Billion |
-2.85pp |
| 2015-12-31 | 11.74% | R$19.65 Billion ≈ $3.86 Billion |
R$167.38 Billion ≈ $32.84 Billion |
-7.82pp |
| 2014-12-31 | 19.56% | R$32.78 Billion ≈ $6.43 Billion |
R$167.57 Billion ≈ $32.88 Billion |
-- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more